# Combat Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/combat-medical

- Industry: Medical Devices & Equipment
- Headquarters: London, UK
- Website: https://combatcancer.com/
- Total disclosed funding: $5M
- Latest round: Series A (Mar 12, 2026)
- Investors on record: 3

## About

Combat Medical Ltd. specializes in advanced hyperthermic cancer treatment technologies, providing innovative systems designed to enhance chemotherapy effectiveness for bladder and peritoneal cancers.Founded in 2011 and headquartered in London, UK, Combat Medical Ltd. focuses on developing innovative medical technologies for cancer treatment. The company has pivoted its strategy towards specialized hyperthermic treatments. The founder, Alberto Albalat, has a background in medical technology, and the current CEO is Edward Bruce-White. Combat Medical specializes in innovative hyperthermic cancer treatment technologies, primarily focused on its proprietary systems for bladder and peritoneal cancers. The company's core products, the BRS HIVEC (Bladder Cancer) and PRS HIPEC (Peritoneal Cancers) systems, utilize advanced heating technologies to enhance the efficacy of chemotherapy treatments. By delivering localized hyperthermic treatment directly to the affected areas, these systems aim to improve patient outcomes by maximizing drug absorption while minimizing systemic side effects. Combat Medical's offerings are employed in hospitals across over 40 countries, serving a diverse clientele that includes healthcare professionals and cancer treatment facilities. The end users of these technologies are primarily bladder and peritoneal cancer patients seeking improved treatment options and outcomes. Combat Medical generates revenue through direct sales of its medical systems to healthcare institutions and partnerships with a global network of distributors to enhance market reach. Transactions typically occur through business-to-business relationships, wherein hospitals and treatment centers procure the BRS HIVEC and PRS HIPEC systems for their oncology departments. The pricing structures reflect the specialized nature and advanced technology of the systems, catering to the unique needs of each healthcare facility. The company is committed to continuous investment in research and development, ensuring its products remain at the forefront of hyperthermic cancer treatment innovation. In March 2026, Combat Medical Ltd. raised GBP 2.6 million in series A funding led by T&J Meyer Family Foundation, with participation from Varia Ventures and NW Angel.

## Funding rounds

- Series A, Mar 12, 2026, $3.5M — NW Angel, Varia Ventures
- Seed, Jan 6, 2014, $0.9M — Oxford Technology Management
- Seed, Apr 2, 2013, $0.7M — Oxford Technology Management

## Investors

- Oxford Technology Management (https://capitalatlas.ai/funds/oxford-technology-management) — Seed
- NW Angel — Series A
- Varia Ventures (https://capitalatlas.ai/funds/varia-ventures) — Series A